Biopharmas in Asia-Pacific raising money in public or private financings: Neurophth.

Exor NV’s acquisition of a 15% stake in Royal Philips NV for approximately €2.6 billion (US$2.8 billion), is a boon for the health care tech company which has been suffering in recent years on the back of a product recall controversy. Netherlands-based diversified holding company Exor will become Philips’ biggest shareholder, and said it is committed to being a “long-term minority investor,” as it grows its investment in the health care sector.

Biopharmas raising money in public or private financings, including: Scisparc, Spexis, TFF.

Biopharmas raising money in public or private financings, including: Benitec, Mind, Mirati, Taysha, Virios.

Biopharmas raising money in public or private financings, including: Abivax, Adlai, Neurophth, Oxurion.

Med-tech firms raising money in public or private financings, including: Shockwave Medical.

Biopharmas raising money in public or private financings, including: 180 Life, Merus, Scisparc, Tango.

Med-tech firms raising money in public or private financings, including: Capstan, Shockwave.

Biopharmas raising money in public or private financings, including: Adarx, Benitec, Georgiamune, Mirati, Nuexone, Protagonist.

Med-tech firms raising money in public or private financings, including: Diality, Invo Bioscience, Neuraxis.